Alpha Cognition Inc. (V:ACOG*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Apr 03, 2024 10:08 pm ET

Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended 2023 and provided a corporate update.

Mar 20, 2024 04:35 pm ET

Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it will present at the Emerging Growth Conference on April 3, 2024. The company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.

Mar 08, 2024 08:35 am ET

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks...

Mar 05, 2024 08:35 am ET

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7th. This event is sponsored by Zacks Small-Cap Research. Individual investors,...

Mar 01, 2024 07:53 am ET

Alpha Cognition to Present at the Life Science Investor Forum March 7th

Alpha Cognition, Inc. (CSE: ACOG)(OTCQB: ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced that Michael...

Feb 22, 2024 08:30 am ET

Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimer’s Disease.

Feb 12, 2024 08:30 am ET

Alpha Cognition Provides Business Update

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update.

Jan 19, 2024 05:34 pm ET

Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company. Pursuant to the final closing, the Company issued 16,965,762 units of the Company at a price of US$0.22 per unit for gross proceeds of US$3,732,467. Each unit consists of a common share and a warrant, with each warrant entitling the holder to purchase an additional common share at a price of US$0.31 for a period of three years. The gross proceeds of the offering received

Dec 22, 2023 04:32 pm ET

Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a fourth closing pursuant to its previously announced private placement of units of the Company. Pursuant to the fourth closing, the Company issued 9,141,534 units of the Company at a price of US$0.22 per unit for gross proceeds of US$2,011,138. Each unit consists of a common share and a warrant, with each warrant entitling the holder to purchase an additional common share at a price of US$0.31 for a period of three years. The gross proceeds of the offering received

Dec 07, 2023 04:35 pm ET

Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its filing review and has accepted the company’s New Drug Application (NDA) for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease. The NDA has been granted a Prescription Drug User Fee Act (PDUFA) goal date of Ju

Dec 04, 2023 08:00 pm ET

Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of units at a price of US$0.22 per unit. Each unit will now consist of one common share and one share purchase warrant. Each warrant will entitle the holder to purchase an additional common share of the Company at a price of US$0.31 per common share for a period of three years from the closing date.

Nov 28, 2023 04:45 pm ET

Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update.

Nov 08, 2023 04:30 pm ET

Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a third closing pursuant to its previously announced private placement of units of the Company. Pursuant to the third closing, the Company issued 4,590,903 units of the Company at a price of US$0.22 per unit for gross proceeds of US$1,009,999. Each Unit consists of a common share and a half warrant, with each whole warrant entitling the holder to purchase an additional common share at a price of US$0.31 for a period of three years. The gross proceeds of the offering

Oct 16, 2023 04:21 pm ET

Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a second closing pursuant to its previously announced private placement of units of the Company. Pursuant to the second closing, the Company issued 1,596,830 units of the Company at a price of US$0.22 per unit for gross proceeds of US$351,303. Each Unit consists of a common share and a half warrant, with each whole warrant entitling the holder to purchase an additional common share at a price of US$0.31 for a period of three years. The gross proceeds of the offering

Sep 27, 2023 04:30 pm ET

Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease. This submission marks a significant milestone in the company's ongoing commitment to advancing patient care for patients s

Aug 31, 2023 07:58 pm ET

Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”) announces the closing of its previously announced private placement of units of the Company for gross proceeds of US$1,345,093 before deducting the placement agent’s fees and other offering expenses payable by the Company. Pursuant to the closing, the Company issued a total of 6,114,058 units at a price of US$0.22 per unit. Each unit consists of a common share and a half warrant, with each whole warrant entitling the holder to purchase an additional common share at a price of $0.31 for a period of three years.

Aug 22, 2023 04:05 pm ET

Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended June 30, 2023, and provided a corporate update.

Aug 14, 2023 05:00 pm ET

Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer’s Disease

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 17/575,025, titled “Solid Forms of ALPHA-1062 Gluconate,” which includes claims covering protection for crystalline solid forms of ALPHA-1062 and will bolster existing patents that the company holds. A Notice of Allowance is issued after the USPTO makes the

Jun 23, 2023 08:35 am ET

Life Science Investor Forum: Presentations Now Available for Online Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Life Science Investor Forum, held on June 22nd are now available for online viewing. REGISTER NOW AT: https://bit.ly/3NuvXOW...

Jun 20, 2023 01:00 pm ET

Canadian Securities Exchange Reports May 2023 Performance Figures

Toronto, Ontario--(Newsfile Corp. - June 20, 2023) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for May 2023.

Jun 20, 2023 10:58 am ET

Life Science Investor Forum Agenda Announced for June 22nd

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER...

Jun 07, 2023 08:30 am ET

Alpha Cognition Receives Army Medical Research Grant for Study on Mild Traumatic Brain Injury (mTBI) from Blast Induced Functional Deficit and Brain Pathology

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the that it has been awarded a $750,000 grant from the Army Medical Research and Material Command (AMRMC) for a pre-clinical study on the use of ALPHA-1062 Intranasal (IN) to reduce blast mTBI induced functional deficit and brain abnormalities.

May 30, 2023 12:15 pm ET

Alpha Cognition Announces First Quarter 2023 Results and Provides Corporate Update

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

May 30, 2023 09:15 am ET

Alpha Cognition Launches $6.5 Million Private Placement

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”) announces a private placement offering of up to $6,500,000 of units at a price of $0.22 per unit. Each unit will consist of one common share and one-half of a share purchase warrant. Each whole warrant will entitle the holder to purchase an additional common share of the Company at a price of $0.31 per share for a period of three years from the closing date. All dollar amounts are in U.S. dollars.

May 10, 2023 08:54 am ET

Alpha Cognition's latest financial growth highlighted by new listing on Canadian Stock Exchange

Alpha Cognition CEO Michael McFadden joins Natalie Stoberman from the Proactive studio to discuss the company's latest financial growth from new funding and reduced expenses and how its been highlighted by a new listing on the Canadian Stock Exchange.

Apr 28, 2023 02:26 pm ET

CSE Bulletin: New Listing - Alpha Cognition Inc. (ACOG, ACOG.WT)

Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.

Mar 16, 2023 11:42 am ET

Alpha Cognition Closes Private Placement

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, is pleased to announce that it has closed a second tranche of its previously announced private placement (the “Offering”) of units (the “Units”). Pursuant to the second tranche, the Company issued 6,952,427 Units of the Company at a price of $0.255 per Unit, for gross proceeds of $1,772,869. Each Unit consists of one common share and one common share purchase warrant, each warrant entitles the holder to pur

Mar 08, 2023 06:24 pm ET

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Mar 06, 2023 05:00 pm ET

Alpha Cognition Provides Private Placement Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, announces that the Company expects to complete the second tranche of its ongoing private placement offering prior to March 17, 2023. Please see the Company’s February 16, 2023 news release for additional information on the offering.

Feb 16, 2023 06:59 pm ET

Alpha Cognition Closes First Tranche of Private Placement

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, is pleased to announce that it has closed the first tranche of its previously announced private placement (the “Offering”). Pursuant to the Offering, the Company issued 16,795,221 units of the Company (the “Units”) at a price of $0.255 per Unit, for gross proceeds of $4,282,781. Each Unit consists of one common share and one common share purchase warrant, each warrant entitles th

Feb 08, 2023 08:37 pm ET

Alpha Cognition Announces $6.8 Million Private Placement

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce a private placement financing of units for gross proceeds of up to C$6.8 million (US$5.0 million). The private placement is expected to close on or about February 15, 2023.

Jan 19, 2023 03:00 pm ET

Alpha Cognition Announces Cancelation and Grant of Stock Options

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced today that it has cancelled an aggregate of 4,655,000 incentive stock options with exercise prices ranging from $0.64 CAD to $1.05 CAD. The board of directors (the "Board") has also approved the grant of options totaling 4,655,000 to certain directors, officers, employees and consultants of the Company at $0.28 per share, with vesti

Jan 06, 2023 06:00 pm ET

Alpha Cognition Announces the Resignation of Chief Medical Officer Cedric O’Gorman, MD

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced that the company's Chief Medical Officer (CMO), Cedric O’Gorman, MD has resigned to pursue other opportunities. The company has undertaken a search for a replacement for Dr. O’Gorman and will maintain its strong relationships with consultants who are assisting the company with its NDA filing.

Nov 28, 2022 04:30 pm ET

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Nov 28, 2022 01:40 pm ET

Alpha Cognition Announces Withdrawal of Marketed Public Offering

Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today...

Nov 18, 2022 07:44 am ET

IIROC Trading Resumption - ACOG

VANCOUVER, BC, Nov. 18, 2022 /CNW/ - Trading resumes in:

Nov 17, 2022 01:52 pm ET

Alpha Cognition Announces Marketed Offering

Nov 17, 2022 01:06 pm ET

IIROC Trading Halt - ACOG

VANCOUVER, BC, Nov. 17, 2022 /CNW/ - The following issues have been halted by IIROC:

Aug 25, 2022 06:48 pm ET

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 22, 2022 09:00 am ET

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Jun 24, 2022 08:35 am ET

Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT:...

Jun 22, 2022 07:00 am ET

Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Jun 21, 2022 04:21 pm ET

UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors,...

Jun 21, 2022 08:35 am ET

Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced that Michael...

Jun 15, 2022 09:00 am ET

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces that the European Patent Office has confirmed the patentability of EP3009143 in amended form following an opposition proceeding involving two opponents. The allowed claims are directed to a composition comprising an effector that increases progranulin expression in neurons or a progranulin polypeptide for use in treatin

Jun 13, 2022 08:30 am ET

Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the discovery of two GEM combinations, ALPHA-0702 and ALPHA-0802, and positive preclinical data from each candidate therapy. ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin (PGRN) which have therapeutic potential across multiple neurodegenerative diseases. GEMs have been shown to be important in regulating cell gro

May 31, 2022 05:38 pm ET

Alpha Cognition Announces Grant of Stock Options

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of stock options pursuant to its stock option plan to certain directors of the Company to purchase up to an aggregate of 400,000 common shares of the Company. The stock options are exercisable at a price of $0.64 CAD per share and expire ten years from the date of grant, subject to certain vesting provisions.

May 31, 2022 08:30 am ET

Alpha Cognition Announces First Quarter 2022 Results and Company Update

Apr 28, 2022 04:15 pm ET

Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update

Apr 12, 2022 09:00 am ET

Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces the appointment of Don Kalkofen as Chief Financial Officer (CFO) to replace Jeremy Wright. Mr. Wright will continue to assist the Company in a consulting capacity.

Mar 29, 2022 09:00 am ET

Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce positive preclinical data from their ALPHA-0602 ALS gene therapy program. These data underscore the robust preclinical evidence supporting Alpha Cognition’s AAV-based gene therapy approach to treating ALS and highlight the Company’s strategy to validate these data in planned clinical trials.

Mar 07, 2022 08:35 am ET

Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10th. This virtual event will showcase live company presentations and interactive...

Feb 22, 2022 08:30 am ET

Alpha Cognition Announces Positive Neuroprotection Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce histology data from their intranasal ALPHA-1062 Traumatic Brain Injury (TBI) program. ALPHA-1062 treatment was neuroprotective, preserving hippocampal structure, reducing cell loss and promoting neurogenesis compared to no treatment. Functional recovery data released in December demonstrated statistically signifi

Jan 03, 2022 09:00 am ET

Alpha Cognition Announces Participation in January Investor Conferences

Dec 27, 2021 04:30 pm ET

Alpha Cognition Announces Director Change and Stock Option Grant

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the resignation of Dr. Fred Sancilio from his role as Director and President of the Company. Dr. Sancilio will continue to work with Alpha Cognition as a consultant focusing on ALPHA-1062’s bioequivalence program.

Dec 20, 2021 07:35 am ET

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-demand viewing.

Dec 20, 2021 07:35 am ET

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Dec 14, 2021 07:35 am ET

Virtual Conference for Life Sciences Companies Broadcast Live December 16th

Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com

Dec 09, 2021 11:19 am ET

Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.

Dec 07, 2021 04:10 pm ET

The Power Play by The Market Herald Releases New Interviews with Rover Metals, Swarmio Media, Nextech AR and Alpha Cognition

VANCOUVER, BC / ACCESSWIRE / December 7, 2021 / The Power Play by The Market Herald has announced the release of a new interview with Rover Metals, Swarmio Media, Nextech AR and Alpha Cognition discussing their latest press releases.

Dec 06, 2021 09:00 am ET

Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program. ALPHA-1062 administration significantly, acutely reduced the extent of the functional deficit, and improved functional recovery of TBI animals compared to untreated animals suffering a TBI. Notably, in four of five functional m

Dec 02, 2021 09:00 am ET

Alpha Cognition Appoints Cedric O’Gorman, M.D., MBA as Chief Medical Officer

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer. Dr. O’Gorman will lead medical, clinical and regulatory functions in support of the company's clinical-stage products ALPHA-1062 and ALPHA-0602. Dr. O’Gorman will also serve as a member of the executive management team, reporting to the CEO.

Nov 30, 2021 09:00 am ET

Alpha Cognition Reports Third Quarter of Fiscal 2021 Results

Oct 08, 2021 09:00 am ET

Alpha Cognition to Present at LD Micro Main Event

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it will be presenting at the 14th annual Main Event on Tuesday, October 12th at 3:00 PM EST at the Luxe Sunset Bel-Air in Los Angeles. Michael McFadden, CEO of Alpha Cognition, will provide an overview of the Company's business, highlighting the Company’s lead asset, ALPHA-1062, as well as its early stage asse

Oct 07, 2021 09:00 am ET

Alpha Cognition Provides CEO Update

Oct 01, 2021 09:58 am ET

Alpha Cognition Announces Closing of $14.4 Million Public Offering

Vancouver, British Columbia--(Newsfile Corp. - October 1, 2021) - ALPHA COGNITION INC. (TSXV: ACOG) (OTCQB: ACOGF) ("Alpha" or the "Company"), is pleased to announce that it has closed its previously announced public offering of units (the "Units") for ‎aggregate gross proceeds of approximately C$14.4 million, including the exercise of the over-allotment option in full (the "Offering"). The Company issued ‎‎9,602,500 Units at a price of C$1.50 per Unit, each Unit consisting of one common share of the ‎Company (a "Share") and one common share purchase warrant (a "Warrant") ‎entitling the holder to purchase one Share at a price of C$1.75 per Share until October 1, 2023. ‎The Company has received approval from the TSX Venture Exchange ("TSXV") to list the Warrants issued pursuant to the Offering, and the Warrants are expected to be listed and posted for trading on the TSXV under the ticker symbol "ACOG.WT" effective on or about October 5, 2021.

Oct 01, 2021 09:00 am ET

Alpha Cognition Announces Formation and Members of Scientific Advisory Board and Investor Relations Agreements

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board (SAB) comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH. The SAB will work cohesively with management to advance the company’s clinical development pipeline and to develop highly differentiated products to treat neurological diseases

Sep 29, 2021 08:30 am ET

Alpha Cognition Updates Anticipated Closing Date of Public Offering

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha" or the "Company"), announces that further to its announcement of the overnight marketed offering through a syndicate of agents led by Raymond James Ltd. and including iA Private Wealth Inc. (collectively, the "Agents") on September 23, 2021, the anticipated closing date of the offering has been extended to October 1, 2021.

Sep 23, 2021 10:18 am ET

Alpha Cognition Announces Pricing of Public Offering

Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to...

Sep 22, 2021 05:08 pm ET

Alpha Cognition Announces Overnight Marketed Offering

Sep 11, 2021 10:03 pm ET

Alpha Cognition, Focused on Neurodegenerative Diseases, CEO Clip Video

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2021) - Alpha Cognition (TSXV: ACOG) (OTCQB: ACOGF) - CEO, Michael McFadden speaks about the company's innovative lead asset - ALPHA-1062.

Sep 09, 2021 08:35 am ET

Alpha Cognition to Webcast Live at Life Sciences Investor Forum September 16th

Alpha Cognition, Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative...

Sep 07, 2021 09:00 am ET

Alpha Cognition Announces the Acceptance of its US FDA Investigational New Drug Application (IND) for Lead Candidate, ALPHA-1062 for Mild to Moderate Alzheimer’s Disease

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce the U.S. Food and Drug Administration (“FDA”) has accepted its Investigational New Drug (IND) application for lead candidate, ALPHA-1062, to proceed with the pivotal clinical phase (the “Pivotal”) of the development program. The Company plans to initiate a Pivotal relative bioavailability study of ALPHA-1062, a prop

Sep 03, 2021 04:31 pm ET

Alpha Cognition Reports Second Quarter of Fiscal 2021 Results

Sep 01, 2021 09:00 am ET

Alpha Cognition to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Aug 20, 2021 09:00 am ET

Alpha Cognition Receives Approval to Commence Trading on the OTCQB

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce the Company's common shares have been approved for quotation on the OTCQB Venture Market ("OTCQB") as at the opening of the market on August 18, 2021. The Company will trade under the stock symbol “ACOGF.”

Aug 09, 2021 09:30 am ET

Alpha Cognition Announces Stock Option Grant

Alpha Cognition Inc. (TSX-V: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of 3,500,000 stock options (“Options”) to certain officers and employees of the Company pursuant to the Company’s stock option plan.

Jul 08, 2021 11:20 am ET

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.

Jun 23, 2021 09:35 am ET

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event.

Jun 03, 2021 08:00 am ET

Alpha Cognition to Host Virtual R&D Day on June 22, 2021

Alpha Cognition Inc. (TSX-V: ACOG) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it will host its first annual Virtual R&D Day for analysts and investors on Tuesday, June 22, 2021, from 1:00PM to 3:00PM EDT. The program will provide a detailed overview of Alpha Cognition’s development strategy highlighting the Company’s deep pipeline across three therapeutic modalities, including Alzheimer’s Disease, Mi

May 04, 2021 09:00 am ET

Alpha Cognition Appoints Lauren D'Angelo as Chief Commercial Officer to Drive Strategic Growth

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce the appointment of Lauren D'Angelo to Chief Commercial Officer. In this role, she will ensure the integrated commercial success of the company. Her initial focus will be to establish the company's commercial strategy to effectively advance and position Alpha Cognition's neurology pipeline, which includes leading all aspects of the U.S. commercial launch of the company's lead program, ALPHA-1062, pending regulatory approval.

Apr 30, 2021 09:00 am ET

Alpha Cognition to Host Investor Webcast on May 6th, 2021

Vancouver, British Columbia--(Newsfile Corp. - April 30, 2021) - Alpha Cognition Inc. (TSXV: ACOG)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it will host a webcast investor presentation on Thursday, May 6th, 2021 at 2:00 PM EDT.

Apr 27, 2021 09:00 am ET

Alpha Cognition Announces Ms. Colleen Johns as SVP, Product Development Further Strengthening the ALPHA-1062 Drug Commercialization Team

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - . Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that Ms. Colleen Johns has been appointed Senior Vice President, Product Development as part of the Company's plan to further develop the operational and commercialization team. Ms. Johns most recently served as the Company's Director of Regulatory Affairs and prior to the Company she has an extensive history with pharmaceutical regulatory approval and commercialization with the U.S. Food and Drug Administration (the "FDA").

Apr 12, 2021 09:00 am ET

Alpha Cognition Announces Mr. Michael McFadden as Chief Executive Officer and Realignment of Leadership Team for Next Stage of ALPHA-1062 Drug Development

Vancouver, British Columbia--(Newsfile Corp. - April 12, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that Michael McFadden has been appointed chief executive officer as part of the Company's plan to accelerate growth. Mr. McFadden most recently served as Chief Commercial Officer of MPower Health, a privately held orthopedic healthcare services company focused on value-based care solutions and interoperative neuromonitoring clinical services.

Mar 30, 2021 04:25 pm ET

IIROC Trading Resumption - ACOG

VANCOUVER, BC, March 30, 2021 /CNW/ - Trading resumes in:

You are here

Alpha Cognition Inc. (V:ACOG*CA)

Business Focus: Biotechnology & Medical Research (NEC)